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Abstract
Design: This randomised crossover trial compared nocturnal auto-adjusting continuous positive airway pressure (APAP)
and nocturnal oxygen therapy (NOT) in adults and children with sickle cell anaemia, with patient acceptability as the
primary outcome. Secondary outcomes included pulmonary physiology (adults), safety, and daily pain during
interventions and washout documented using tablet technology.
Methods: Inclusion criteria were age > 8 years and the ability to use an iPad to collect daily pain data. Trial participation
was 4 weeks; week 1 involved baseline data collection and week 3 was a washout between interventions, which were
administered for 7 days each during weeks 2 and 4 in a randomised order. Qualitative interviews were transcribed
verbatim and analysed for content using a funnelling technique, starting generally and then gaining more detailed
information on the experience of both interventions. Safety data included routine haematology and median pain days
between each period. Missing pain day values were replaced using multiple imputation.
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Results: Ten adults (three female, median age 30.2 years, range 18–51.5 years) and eleven children (five female, median
age 12 years, range 8.7–16.9 years) enrolled. Nine adults and seven children completed interviews. Qualitative data
revealed that the APAP machine was smaller, easier to handle, and less noisy. Of 16 participants, 10 preferred APAP
(62.5%, 95% confidence interval (CI) 38.6–81.5%). Haemoglobin decreased from baseline on APAP and NOT (mean
difference −3.2 g/L (95% CI −6.0 to −0.2 g/L) and −2.5 g/L (95% CI −4.6 to 0.3 g/L), respectively), but there was no
significant difference between interventions (NOT versus APAP, 1.1 (−1.2 to 3.6)). Pulmonary function changed little.
Compared with baseline, there were significant decreases in the median number of pain days (1.58 for APAP and 1.71
for NOT) but no significant difference comparing washout with baseline. After adjustment for carry-over and period
effects, there was a non-significant median difference of 0.143 (95% CI −0.116 to 0.401) days additional pain with APAP
compared with NOT.
Conclusion: In view of the point estimate of patient preference for APAP, and no difference in haematology or
pulmonary function or evidence that pain was worse during or in washout after APAP, it was decided to proceed with
a Phase II trial of 6 months APAP versus standard care with further safety monitoring for bone marrow suppression and
pain.
Trial registration: ISRCTN46078697. Registered on 18 July 2014
Keywords: Sickle cell anaemia, Inherited diseases, Haemoglobin, Qualitative method, Statistical method, Randomised
crossover trial
Introduction
There is a high prevalence of obstructive sleep apnoea
(OSA) [1] and overnight oxygen desaturation [2] in chil-
dren and adults [3] with sickle cell anaemia (SCA, HbSS,
or HbSβ 0-thalassaemia). In the general population, con-
tinuous positive airway pressure (CPAP) is an established
treatment for OSA in adults and children [4–6], and
oxygen supplementation plays a role in the management
of chronic obstructive pulmonary disease [7, 8] in adults
and of bronchopulmonary dysplasia in children, respect-
ively. However, there are few data on the acceptability or
efficacy of either method of respiratory support in SCA.
This is in part due to concerns about the safety of oxy-
gen administration in this condition, specifically with re-
spect to bone marrow suppression and rebound pain
[9–11]. Optimal management of nocturnal desaturation
therefore remains controversial, and the possibility that
reducing exposure to hypoxia might reduce SCA com-
plications has received little attention.
Auto-adjusting continuous positive airway pressure
(APAP), which increases airway pressure when the pa-
tient’s airway obstructs, appears to improve attention/
processing speed, measured as cancellation, and reduce
pain episodes in children with SCA [12]. CPAP has been
used peri-operatively in adults with sickle cell disease
(SCD) [13] but, although the results of a Phase II study
are awaited [14], there are as yet no published data on
longer term use in adults. However, there is observa-
tional evidence that nocturnal oxygen therapy (NOT),
used for a period of at least 6 months in adults with
SCA and severe nocturnal hypoxia, is safe and easy to
use [11]. It is not known whether patients would prefer
one of these treatments over the other, an essential pre-
requisite for a two-arm Phase II trial comparing either
method of overnight respiratory support with standard
treatment [14].
The Prevention of Morbidity in Sickle Cell Disease
(POMS2a) study is a National Institute for Health Re-
search (NIHR) Research for Patient Benefit (RfPB)
funded pilot crossover trial to compare APAP with NOT
in adults and children with SCA to identify: 1) the treat-
ment strategy most acceptable to patients and families
for further investigation; 2) whether there are likely
short-term safety concerns (e.g. worsening anaemia or
pain), or physiological benefits (e.g. pulmonary function)
or clinical benefits (e.g. reduced pain) for overnight oxy-
gen therapy or APAP; 3) the feasibility of completing a
pain diary as an app on an iPad to collect daily informa-
tion on site and severity of pain; and 4) the main cost
drivers and potential cost implications of providing the
intervention [15].
Methods
Inclusion and exclusion criteria
This was a randomised crossover trial of APAP and
NOT (Fig. 1) conducted at Guy’s and St Thomas’ Hos-
pital NHS Foundation Trust [15]. Inclusion criteria in-
cluded: age over 8 years, a diagnosis of SCA, the ability
to speak English, gave informed consent or assent, and
could use an iPad. Exclusion criteria included: current or
prior experience with overnight respiratory support, hos-
pital admission for acute sickle complications within the
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past 1 month, > 6 admissions for acute sickle complica-
tions within the past 12 months, existing respiratory fail-
ure, decompensated cardiac failure, pregnancy, and
contraindications to APAP [15].
Baseline data
Baseline haematology, oximetry, medical, and quality of
life (PedsQL) [16, 17] questionnaires and 1 week of base-
line pain data were obtained. Overnight oximetry was
measured at home over two nights at baseline to docu-
ment mean and minimum overnight oxygen saturation,
but evidence of overnight hypoxia and/or OSA was not
necessary for inclusion in the trial.
Randomisation and blinding
Patients were randomly assigned to receive APAP or
NOT for 1 week, followed by 1 week washout and then 1
week of the alternative intervention. In view of previous
concerns about safety [9, 10], which the children might
not have been able to articulate, the adult participants
were randomised first. Variable block randomisation of
the order of treatment (APAP/NOT) was undertaken by
an independent statistician at the University of Southamp-
ton. It was not possible to blind the participant, local Prin-
cipal Investigators, study co-ordinator, sleep physiologist,
or psychologist to the order of treatment. However, the
Chief Investigator, statistician, and technician performing
spirometry, i.e. those responsible for documenting the
quantitative endpoints, were blinded to which interven-
tion was given in which order.
Intervention
The REMstar® Auto System (Philips Respironics) is an
APAP device designed for the treatment of OSA. When
set in the APAP mode, the system monitors breathing
whilst sleeping and automatically adjusts the pressure to
overcome upper airway obstruction. APAP was set at 4
cmH2O with an upper limit of 10 cmH2O administered
via a nasal or oral-nasal mask. For NOT, oxygen concen-
trators (Philips Respironics) were used to administer
oxygen therapy at 0.5 L/min in children and 1 L/min in
adults via nasal cannula or mask depending on partici-
pant preference.
Compliance
Support from a respiratory physiologist with experience
of APAP and NOT was available to initiate and
maximize compliance with the interventions. For the
APAP intervention, compliance with treatment was for-
mally assessed using Encore Pro™ data management soft-
ware via a SmartCard that recorded both qualitative and
quantitative data on a single card collected after the 7-
day intervention period. For the oxygen therapy, the
sleep physiologist telephoned participants 24 h after
starting each intervention and mid-treatment and kept a
record of telephone support during the study.
Primary outcome: patient preference
The primary outcome was patient preference assessed
via semi-structured interviews that explored participant
experience with each intervention and the electronic
pain diary app.
Semi-structured interview guide
All qualitative interviews were conducted using a semi-
structured interview guide. The interview guide was
structured using a funnelling technique, which started
with a general question about prior experience and ex-
pectations of different treatments and then worked to-
wards gaining detailed information about the experience
of using the interventions. Initial probing questions were
open ended, such as “Can you tell me more about that?”
Additional probing questions asked about different types
of influences including people at home, environmental
factors such as space, and others. On principle, neither
the questions nor analysis were directed by theory. At
the end of the interview, the participant was asked if
there was any other information that would be import-
ant in understanding her or his treatment choice. The
interview guide evolved throughout the course of the
Fig. 1 Design of the POMS2a randomised crossover study of auto-adjusting continuous positive airways pressure (APAP) and nocturnal oxygen
therapy (NOT) in sickle cell anaemia
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study to explore developing concepts; however, each par-
ticipant was asked about the same main focal areas to
ensure dependability in the data.
Data collection
After participants were re-consented over the telephone,
the interview guide was followed with flexibility for the
informant’s pace, comfort, and expression. Field notes
about the interaction were transcribed immediately fol-
lowing the telephone call.
After transcribing the interviews with participants who
had completed both interventions, content analysis was
used to analyse the data. Content analysis is the process
of subjective interpretation of text data through system-
atic classification of coding and identifying themes and
patterns [18]. Specifically, this dataset was examined
using conventional content analysis, a method that is
used to describe a phenomenon by allowing codes to
flow from data and is focused on the surface meaning
on the words being analysed. Through this methodology,
codes are developed after reading and re-reading the text
for 3–4 transcripts and then applied to the rest of the
data. If the new data does not fit into a previous code, a
new code is developed and, finally, codes are assimilated
based on similarity [18].
Content analysis was deemed appropriate due to the
quantitative and qualitative nature of the data. Both
open-ended and close-ended questions were used to as-
certain patient feasibility, acceptability, and preference.
Through content analysis, both the frequency of a spe-
cific response (i.e. preference for APAP over NOT)
could be counted and participant anecdotes could be
noted. This gives an objective method to quantify re-
sponses, as well as derive anecdotal meaning behind the
numbers. A conventional method was used as opposed
to a directed or summative method due to the limited
background on the usage of APAP (or any form of over-
night respiratory support) in SCA patients [19].
The content analysis began by the researcher reading
through the transcript as a whole and then returning to
focus on the first four transcribed interviews. These four
transcribed interviews were read thoroughly and keywords
describing answers to the semi-structured interview ques-
tions were highlighted. After highlighting the transcripts,
the keywords were sorted into codes that encompassed
similar themes. Thereafter, the codes were further sorted
under categories and subcategories to create an organized
and systematic way to consolidate and analyse the data.
For example, three main categories were created to separ-
ate attitudes prior to treatment, experiences during treat-
ment, and post-treatment thoughts. After creating a
master list of codes for both adults and children, the
remaining transcripts were highlighted and then trans-
ferred into the coding sheets. Wherever a question evoked
a response that did not fit into the coding sheet, it was
noted and added as miscellaneous until a relevant code
was created. In the final step, the master list of codes was
re-evaluated to see that codes were exhaustive, mutually
exclusive, and independent.
Secondary endpoints
Secondary endpoints were focused on addressing concerns
about safety, specifically the possibility of rebound pain dur-
ing the washout period [9] and of bone marrow suppres-
sion during 1 week of treatment manifest as reduced
erythropoietin, reticulocyte count, red cell count, haemo-
globin and haematocrit levels [9], or of haemolysis manifest
as an increase in bilirubin or lactate dehydrogenase [20].
In addition to documenting admissions for pain as se-
vere adverse events, iPad mini-tablet technology [21]
was used to collect daily pain scores for the week imme-
diately before the first intervention, during the first
intervention, during washout from the first intervention,
and during the second intervention. The majority of the
children managed the app by themselves but some of
the younger children were assisted by their parents.
Confidentiality
The paper data were stored in a locked cupboard and
the electronic data were anonymised and stored on a
password-protected computer.
Sample size
This was a pilot trial [15] to determine patient preference
for a Phase II study [14]. We wanted to include adults as
well as children in this pilot since obstructive sleep apnoea
and nocturnal oxygen desaturation have been described in
all age groups but the only previous pilot trial included
only 24 children [12]. It was not considered appropriate to
include a power calculation, but we found no evidence for
bone marrow suppression or rebound pain in 12 children
on APAP in the previous pilot trial [12]. We therefore
aimed to recruit around 10 adults and 10 children in this
pilot crossover trial of two possible treatments to test the
safety of the alternative interventions and the feasibility of
running such a study [15] before beginning the Phase II
trial [14]. Twenty patients (10 children and 10 adults)
were considered sufficient for the qualitative interviews
for the primary endpoint.
Statistical analysis
Qualitative and quantitative data are reported according
to the planned statistical analysis [15].
Additional statistical analysis to account for missing data
The number of pain days reported was compared be-
tween periods (baseline, wash-out, and both treatment
periods) using a bootstrap 95% confidence interval (CI)
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of the within-person median difference. This difference
was given before and after adjusting for potential period
and carry-over effects.
To overcome the problem of missing data, multiple
imputation was used to impute the binary variable repre-
senting pain or no pain; 100 imputations were carried
out. The package ‘mi’ was used in R [22], and the vari-
ables included in the model were subject ID, day of
treatment, and intervention. As the variable of interest
(number of pain days within a week) was not normally
distributed, bootstrapping [23] was used with 10,000 it-
erations to estimate the distribution of median pain
days, which was normally distributed around the me-
dian. The mean and standard deviation of the 100 imputed
distributions were used to give estimates of the median and
variance (calculated from the bootstrap standard error esti-
mate and the sample size) of the within-imputation me-
dians, which could then be combined using Rubin’s rules
[24]. Note that this process, whilst giving the optimal esti-
mates of the median numbers of pain days, does not neces-
sarily yield integer values. A similar process was used to
obtain 95% CIs for the differences between baseline and
washout measures, treatment, period, and carry-over effects
[25]. The intention of these analyses was not to determine
whether one treatment was significantly better than the
other but to gain information on the effect size necessary to
inform a future adequately powered trial of treatment.
Sensitivity analyses considered the ‘best case sce-
nario’ where all missing values were recorded as no
pain, and the ‘worst case scenario’ with all missing
values recorded as pain days.
Results
Participants
Thirteen adults were screened; three declined, citing up-
coming holidays (n = 2) and inconvenience due to living
with many relatives. Thirteen children were screened;
one declined because of claustrophobia and unwilling-
ness to use a mask and one was not recruited as the
study had finished. Ten adults (three female, median age
30.2 years, range 18–51.5 years) and eleven children (five
female, median age 12 years, range 8.7–16.9 years) were
enrolled (Table 1). The additional child was recruited be-
cause a child did not tolerate the first intervention and
withdrew within 24 h of a month-long study, precluding
appropriate assessment of the primary or most second-
ary endpoints (see below).
Oximetry at baseline
Compared with the normative data in children and
adults undergoing overnight polysomnography and ox-
imetry but with a Respiratory Disturbance Index (RDS)
< 5 [26] and children in the asymptomatic general popu-
lation undergoing overnight oximetry with or without
polysomnography [27–29], mean and minimum over-
night oxygen saturation (SpO2) before randomisation
was abnormal in the majority of adults and children
(Table 1). In the five adults on hydroxyurea to maximum
tolerated dose, mean overnight SpO2 was lower (mean
92 ± 2.8% vs 93.2 ± 3.0%) but nadir SpO2 was slightly
higher (78.9 ± 7.5% vs 76.4 ± 76.3%). The pattern was
similar for children, with lower mean SpO2 (92.2 ± 4.5%
vs 95.1 ± 2.6%) but slightly higher nadir SpO2 (78.6 ±
4.5% vs 77.7 ± 2.9%) in the six children on hydroxyurea.
None of these differences were statistically significant.
Quality of Life
Table 2 shows the results for the PedsQL quality of life
measure at baseline. We used the validated sickle module
for the children and the adult version of the PedsQL for
the adults. For the children, the data from a large study of
PedsQL in children with SCD [30] are shown for compari-
son. For most domains, scores appeared higher, i.e. better
health-related quality of life, in the small sample of nine
children completing the sickle module of the PedsQL in
our study. Only two children and four adults completed
follow-up PedsQL questionnaires (data not shown), citing
lack of time at follow-up appointments.
Table 1 Patient characteristics
Adults (n = 10) Children (n = 11)
Male, n (%) 7 (70%) 6 (55%)
Receiving hydroxyurea, n (%) 5 (50%) 6 (55%)
Interviewed, n (%) 9 (90%) 7 (64%)
Nadir SpO2 < 2 standards below
mean for age for people with
RDI < 5 [26], n (%)
9 (90%) 9 (82%)
Mean SpO2 < 10th centile
(96% [27]), n (%)
9 (90%) 9 (82%)
Nadir SpO2 < 10th centile
(93.5% [27]), n (%)
10 (100%) 11 (100%)
Nadir SpO2 < 2.5th centile
(85.2% [28]), n (%)
8 (80%) 9 (82%)
Nadir SpO2 < 2 standards
below mean (86.8% [29]) , n (%)
9 (90%) 9 (82%)
Age (years), median (range) 30.2 (18–51.5) 12 (8.7–16.9)
Overnight oximetry over 2
nights, median (range)
Mean SpO2 Median (range) 92.6 (87.7–97.3) 95.4 (85.0–97.7)
Nadir SpO2 Median (range) 79 (65.5–87.4) 81.1 (73.7–90.7)
APAP adherence, median (range)
Nights used 6 (3–7) 7 (1–7)
Hours per night over 7 days 4.12 (0.55–6.77) 6.18 (0.75–9.19)
Hours per night over nights used 5.67 (1.27–7.83) 6.18 (2.79–9.19)
APAP auto-adjusting positive airway pressure, RDI Respiratory Disturbance
Index, SpO2 oxygen saturation
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Qualitative endpoint
Detailed semi-structured qualitative interviews were com-
pleted for nine adults and seven children. The majority of
participants (10/16; 62.5% (95% CI 38.6–81.5%)) showed a
preference for APAP because the machine was smaller,
easier to handle, and less noisy, and they preferred the
idea that it would only correct breathing when abnormal.
However, participants found the mask for APAP uncom-
fortable, although they noted that they slept better when
using the APAP machine and were less fatigued (Table 3).
Patients reported that NOT had a calming effect on
them, but they also reported that it was very noisy
and caused a dry nose, throat, and mouth (Table 3).
Serious adverse events
Two patients (one child; 9.5% (95% CI 3–29%)) were
admitted with pain whilst in the APAP arm and
were withdrawn from the trial. The adult completed
3 days of APAP at an average of 7.61 h and was ad-
mitted 2 days later with a painful crisis and subse-
quent acute chest syndrome. The child who did not
tolerate APAP, and who stopped after using it for
5.26 h on 1 night, was admitted with a painful crisis
3 days later. No patients were admitted with pain
whilst in the NOT arm but one adult (5% (95% CI
1–23%)) developed a pain crisis on day 2 of NOT
which was self-managed at home.
Haematological and biochemical safety
Haemoglobin and red blood cell count decreased after
both interventions with similar mean differences
(Table 4). One patient showed a decrease in absolute
reticulocyte count from 128 × 109/L to 53 × 109/L at the
end of NOT therapy, with no change in haemoglobin.
Haemoglobin less than 60 g/L was not seen and there
were no significant differences in reticulocyte count or
erythropoietin, or in creatinine, the albumin:creatinine
ratio, bilirubin, or lactate dehydrogenase levels after ei-
ther intervention compared with baseline (Table 4).
Lung function
Lung volume measures did not increase on APAP and
there was little change in lung function after 1 week of
either APAP or NOT in the adults (Table 4).
Adherence
APAP adherence data are presented in Table 1. Two-
thirds of the patients (eight children and six adults) ad-
hered to APAP for more than 5 h for 6 or 7 nights. Ad-
herence was a little better in the children in terms of the
number of hours per night, perhaps because they were
not sharing a bed and were supervised by their parents.
However, one child refused to use the APAP machine at
all after a very short trial on the first night. One adult
ceased use of the APAP machine on becoming unwell
with a cold. Further details of the qualitative experiences
Table 2 Quality of life at baseline
PedsQL sickle cell disease
module scales
Number
of items
This study Panepinto et al. [30]
n Mean SD % Floor % Ceiling n Mean SD % Floor % Ceiling
Child self-report
SCD total score 43 9/11 240 62.4 18.6 0 0.6
Pain and hurt 9 9/11 81.2 21.4 0 11 243 66.7 20.9 0 5.3
Pain impact 10 9/11 71.4 24.4 0 11 239 54.0 24.8 0.3 5.6
Pain management and control 2 9/11 80.6 19.9 0 44 235 54.9 29.9 7.5 10.6
Worry I 5 9/11 71.1 19.6 0 11 240 63.5 26.2 0.9 10.0
Worry II 2 9/11 94.4 11.0 0 78 182 73.4 29.7 3.7 22.1
Emotions 2 8/11 54.7 35.9 13 25 238 62.0 33.1 8.4 19.3
Treatment 7 8/11 79.9 21.2 0 25 237 64.3 21.9 0.3 4.0
Communication I 3 8/11 76.0 21.6 0 37.5 239 73.8 24.9 0.3 23.4
Communication II 3 8/11 59.4 45.1 13 37.5 236 57.2 30.5 4.7 13.4
Adult core PedsQL
Physical 8 10/10 64.4 26.8 0 0
Psychosocial 15 10/10 75.2 18.3 0 0
Emotion 5 10/10 74.0 19.3 0 20
Social 5 10/10 77.5 21.5 0 20
Work 5 10/10 74.0 19.4 0 10
SCD sickle cell disease, SD standard deviation
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Table 3 Qualitative analysis
Overarching
category
Question and response Quotes
Semi-structured
interview
responses for
children (n = 7)
Attitudes prior to
study
Reason(s) for participating
• Doctor recommendation (1)
• Personal reasons (1)
• Research reasons (3)
• Do not know (2)
“My son is out of
breath every
morning and his
eye are always
yellow”
Prior knowledge about
treatment
• None (6)
• Knowledge from previous
experience (1)
“Sometimes when
he has an asthma
attack he uses the
oxygen”
Experience of
treatment
Cons of APAP or oxygen
• Issues with machine
apparatus (4)
• Physiological side effects (1)
• Uncomfortable sensations
(1)
[APAP]
“Sometimes it [the
mask] keeps
coming out and
you have to put it
back so it was just
a bit problematic”
[APAP] “Need to
take it [the
machine] off to
breathe”
Changes in symptoms or
day-to-day life
• None (4)
• Physical differences (1)
• Alertness/consciousness
differences (3)
• Sleep patterns:
– (negative) (1)
[NOT] “…eyes was
clear or very
white… it wasn’t
last for longer all
day, but for a few
hours”
Experiences with
the machine
Difficulties using the machine
• Yes (0)
• No (7)
Post-treatment
thoughts
Most preferred machine
• APAP (4)
• NOT (3)
Advice for future users
• Recommendation based
on own preference (2)
Advice for researchers
• Changes to machines (1)
• Changes to protocol
[APAP] “Some
people don’t have
much space, so to
make it secure
would be hard”
Semi-structure
interview responses
for adults (n = 9)
Attitudes prior to
study
Reason(s) for participating
• Doctor recommendation (3)
• Personal reasons (2)
• Research reasons (1)
• Help others (1)
• Personal and research (2)
• Personal and help others (2)
• Do not know (1)
“Benefit me now
or in the future
and other sickle
patients…
thought the trial
could possibly
help in the future
if I need it or
somebody else
needed that kind
of treatment.”
“Always willing to
Table 3 Qualitative analysis (Continued)
Overarching
category
Question and response Quotes
help with the
advancement of
medical research”
“I would really and
truly hope it
would benefit the
sicklers behind
me…Cause for
myself.. I think I
am long over the
age now”
“for the first time I
was going to get/
receive something
in return for doing
the study”
Prior knowledge about
treatment
• None (7)
• Knowledge from previous
experience (2)
“I know oxygen
calms you down
when you take
injections and
stuff like that”
Expectations of study
• None (5)
• Help with sickle cell
symptoms (3)
• Help with sleep (2)
“Oxygen levels
would be better
and help manage
my pain”
“Figure they [the
machines] would
help me during
the night”
Concerns of study
• None (10)
• Health (0)
• Social (1)
“My concern is
that it [the APAP
machine] would
fall and wake
everyone”
Experience of
treatment
Overall experience
• Indifferent (2)
• Positive (5)
• Negative (2)
Pros of APAP or oxygen
• Physiological factors (2)
• Technical factors (7):
- APAP (5)
- Oxygen (2)
• Overall mood (4)
[APAP] “It was a
bit more
intelligent in
regards to... it
would
compensate for
any air loss that
you was breathing
in”
[APAP and NOT]
“made me feel
more relaxed”
[NOT] “…
especially at
winter, in the
night when you
feel funny and
your breathing is
funny. It’s when
you have it in the
bedroom before
the ambulance
comes. That
equipment, you
can put in your
mouth.. and that
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Table 3 Qualitative analysis (Continued)
Overarching
category
Question and response Quotes
will help you
oxygen levels as
well before the
ambulance
arrives…and then
they can give you
more assistance to
get to the
hospital”.
Cons of APAP or oxygen
• Issues with machine
apparatus (11)
- APAP (6)
- Oxygen (7)
• Physiological side effects
(3)
- APAP (1)
- Oxygen (2)
• Uncomfortable sensations
(1)
• Social factors (1)
[APAP] “The mask
over my face is a
bit restrictive for
moving around”
[NOT] “The noise
the machine
made was louder”
[APAP] “Made my
throat a bit dry
and it felt like… it
feels that way…
like I am catching
a cold”
[APAP] “I felt like I
was suffocating”
“I think it was just
in terms of a
family getting
used to the
machine”
Changes in symptoms or
day-to-day life
• None (4)
• Physical differences (5)
- Positive: (4)
- Negative: (1)
• Alertness/ consciousness
differences (6)
- Positive: (5)
- Negative (1)
• Sleep patterns (13)
- Positive: (10)
- Negative: (3)
• Eating pattern (1)
[APAP and NOT] “I
didn’t have as
many headaches
[in the morning]”
[APAP and NOT] “I
wasn’t tired
during the day”
[NOT] “It felt when
the room was hot
and stuffy, I was
still able to get a
good oxygen
supply”.
[APAP and NOT] “I
was able to get
more sleep and
uninterrupted
sleep. Sometimes
without the
machine I will
wake up in the
middle of the
night because my
mouth is dry or
something like
that. With the
machine, none of
that happened”.
[APAP]
“Sometimes I felt
like I couldn’t
sleep through the
night
completely… But
as the days got
by, I got used to
it.”
Table 3 Qualitative analysis (Continued)
Overarching
category
Question and response Quotes
Experience with the
machine
Difficulties in using the
machine
• Yes (0)
• No (9)
[APAP] “Very easy.
Easy to manage.
Light machine…
no problems”
[NOT] “No it’s a
very simple
machine. You just
press the button
once, press it
again and you
configure it once
and it stays like
that”
Post-treatment
thoughts
Most preferred machine
• APAP (6)
• Oxygen (3)
“The mask is more
comfortable to
sleep [APAP] with
at night. With the
other one [NOT]
the mask is too
big... it was hard
for me to sleep.”
Advice for future users
• Recommendation based
on own preference (7)
• None (2)
Advice for researchers
• Related to machines (5)
• Related to protocol (2)
• None (2)
“Interface for pain
diary is primitive”
“[make the mask]
more comfortable
to wear and sleep
with at night.”
[NOT] “Would take
a lot longer to get
used to”
More questions
• About questionnaire (1)
• Related to machines (1)
Overall experience
with pain diary
• Positive (9)
• Other (2)
“If I was having a
bad day, it did ask
more questions
but I think that
was fine… the
way it is”
“the interface…
the actual thing
that you fill out.. it
does look
slightly…
primitive I would
say….it doesn’t
really matter
realistically… but
you want a nicer
interface”
“I had no
incentive to fill in
the pain diary
when I was pain-
free”
APAP auto-adjusting continuous positive airway pressure, NOT nocturnal
oxygen therapy
Howard et al. Trials          (2019) 20:442 Page 8 of 15
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of APAP and NOT treatments in the adults and children
are given in Table 3.
Pain
iPad data were available for 70.4% of days. Data were miss-
ing for a variety of reasons, for example patients unable to
use the iPad or forgetting to record data. There was no in-
dication that the missing pain days were directly related to
the pain itself and so it was assumed for the imputation
analyses that all missing values were either missing com-
pletely at random or missing at random. All patients were
analysed on an intention-to-treat basis.
The median number of pain days per week were 2 for
baseline, and 0 for washout, APAP, and NOT (number
of observations reported were 112, 97, 99, and 106 re-
spectively out of a potential 21 × 7 = 147 measures per
period) (Table 5). Only two participants recorded on
every day; others missed between 1 and 23 days. After
imputation of missing pain days, these medians stayed at
2 per week for baseline and 0 per week for APAP, but in-
creased to 1 for washout and NOT assessment times.
The within-person difference in the median number of
pain days between baseline and the washout period was
non-significant (median difference 1.02 days (boot-
strapped 95% CI −0.146 to 2.18)), and thus there was no
evidence that a week was not sufficient time to return to
baseline. Conclusions were similar for both sensitivity
analyses. Both APAP and NOT were associated with a
reduced number of median pain days when compared
with baseline (1.58 and 1.71, respectively). Sensitivity
analyses (best and worst case scenarios) showed the
same direction of difference, but this was no longer sig-
nificant (Table 6).
The results above did not adjust for any carry-over or
period effects. A further analysis was carried out to cal-
culate these effects as well as an adjusted treatment ef-
fect to compare NOT and APAP; these results are
displayed in Table 7.
The estimated carry-over effect was higher for NOT
compared with APAP but was not statistically significant
(median difference 0.98 (95% CI −0.52 to 2.48)). A non-
significant period effect showed that there were on aver-
age 0.26 fewer (95% CI −0.52 to 0.001) pain days for the
treatment given in the second period; the direction of
this effect differed between best-case analysis and the
multiple imputation and worst-case results. Adjustment
for period and carry-over effects attenuated the differ-
ence in treatment regimes, giving a median decrease in
pain days of 0.14 for APAP compared with NOT (95%
CI −0.12 to 0.40). Hence, the results were not compat-
ible with any meaningful difference in the number of
pain days between the two treatments.
Cost of the interventions
The cost of a standard oxygen concentrator is about
three times that of an APAP machine (£1025 vs £330 in
2013). The APAP machine is light enough to take on
holiday while a semi-portable oxygen concentrator on a
trolley costs £2500. Consumables (masks, tubing) are
about 10 times more expensive for APAP (£150 vs £15)
but, if fitted correctly, an APAP mask may last for over a
year, while oxygen masks and tubing may be discarded
more frequently. One family using coins for electricity
noticed that they were using more electricity during the
week on NOT.
Discussion
Primary endpoint
This study shows that patients with SCA are willing, in
principle, to participate in research involving overnight
respiratory support, at least at the exploratory stage.
Neither APAP or NOT is an ideal therapy from the pa-
tient’s point of view, but the inconvenience and discom-
fort of the mask essential for APAP is preferred to the
noise of an oxygen concentrator, for which a mask is op-
tional. Around 1 in 10 patients did not tolerate over-
night respiratory support for 1 week but from the pain
diaries there was no evidence for rebound pain in the
washout period after 1 week of intervention. There was
little evidence for clinically significant bone marrow sup-
pression with either therapy. However, this was a very
small pilot study and more data are needed.
Despite clear indications that overnight oxygen supple-
mentation using CPAP, APAP, or oxygen therapy can
help improve the quality and life expectancy for patients
with OSA in the general population, adherence rates re-
main between 45 and 70% [31–34]. Considering the low
usage rates in OSA patients, it is logical to assume that
Table 5 Number of pain days
Data Baseline APAP Washout NOT
Raw 2 (1, 3) 0 (0, 0) 0 (0, 1) 0 (0, 1)
Multiple imputation (100 imputations) 2 0 1 1
Best case (all 0) 2 (1, 3) 0 (0, 0) 0 (0, 1) 0 (0, 1)
Worst case (all 1) 3 (3, 4) 2 (1, 5) 3 (1, 4) 4 (1, 6)
Values are shown as median (95% bootstrap confidence interval from 10,000 bootstraps)
APAP auto-adjusting continuous positive airway pressure, NOT nocturnal oxygen therapy
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similar factors that prevent OSA patients from using
CPAP or APAP would apply to patients with SCA. Our
data agree with these adherence rates for APAP. How-
ever, five patients (24%) were not considered adherent to
APAP and two withdrew because they were admitted to
hospital after receiving APAP for 1 and 3 days, respect-
ively. We were unable to obtain similar data for NOT
usage as the NOT machines did not have the capability
to download adherence data. Participants told the co-
ordinator that they had used the concentrator over the
short period of the intervention, but we were not able to
document how compliant they had been. The use of oxy-
gen cylinders is an alternative which would enable the
amount used to be calculated but there are concerns over
fire risk, and the cylinders are bulky in the domestic setting.
Many patients decide whether to use CPAP early on in
the treatment period, usually within the first week of
treatment [35, 36]. After 1 week of treatment exposure,
cognitive factors such as self-efficacy and perceptions of
disease risk and treatment outcome have been identified
as significant independent predictors of CPAP use both
in the short (i.e. 1 month) and long term (i.e. 6 months)
[32, 37, 38]. However, cognitive perceptions influence
CPAP use only within the context of knowledge of CPAP
treatment and treatment use [39].
Various attempts have been made to identify factors
that predict short- and long-term adherence; however,
the data remain largely equivocal [34]. In general, across
age groups, factors that influence or predict CPAP use
include: a) disease and patient characteristics (e.g. age,
socio-economic status), b) treatment titration procedure,
c) technological device factors and side effects (e.g.
mask, heated humidification), and d) psychological and
social factors (disease- and treatment-specific know-
ledge, presence of bed partner, maternal education) [33].
In terms of technological device factors and side ef-
fects, the comfort of the mask features prominently as a
factor that influences adherence in PAP machines [33,
40]. A systematic review by Saywer et al. [33] concluded
that, although the mask is often a point of contention,
there has not been in-depth research about its effect on
adherence; however, a full mask overall is associated
with lower adherence than a nasal tube for CPAP. How-
ever, one participant in the current study found the nasal
tube unbearable and preferred the mask. Prashad et al.
[40] concluded that, although almost all users of CPAP
found the mask uncomfortable, patients who regularly
used CPAP found that the benefits of the treatment out-
weighed the mask’s discomfort. In this current study, five
adults and three children expressed discomfort with the
mask, with one participant finding the comfort level
something she could not bear. In terms of oxygen ther-
apy, three adults expressed an annoyance for the nasal
cannula falling out at various points in the night. One
child said that this frequent disconnection kept him up
all night, and the mother reciprocated this by claiming
she had to tape the nasal cannula to prevent it from fall-
ing out. This concern, however, is not reflected in the
current literature for oxygen therapy.
The difference in pressures between the oxygen ther-
apy and APAP also plays a role in comfort, specifically
in APAP. On one hand, researchers thought the lower
overall pressure throughout the night helped facilitate a
preference for APAP; however, another study [31] dis-
cussed that the high pressures (that would be imple-
mented when the patient stops breathing) caused an
unpleasant sensation. Both these thoughts were reflected
in certain ways in the interviews from the POMS2a trial.
Three participants claimed that they preferred the pres-
sure in the APAP machine because “it felt like [they]
were taking in more oxygen” compared with the noctur-
nal oxygen. On the other hand, one adult and one child
expressed that the high pressure of the APAP machine
at certain points made them feel like they were suffocat-
ing, thus causing unpleasant sensations. Lastly, the noise
and size of the machines also played a role in patient
Table 6 Difference in the number of pain days between interventions
Method Baseline – washout Washout –APAP Washout – NOT Baseline – APAP Baseline – NOT APAP – NOT
Multiple imputation 1.02 (−0.146, 2.18) −0.249 (−1.12, 0.536) −0.244 (−1.23, 0.738) 1.58 (0.509, 2.65) 1.71 (0.791, 2.62) −0.00569 (−0.385, 0.373)
Best case 1.00 (0, 2.00) 0.00 (0.00, 1.00) 0 (−1.00, 0.00) 1.00 (0.00, 2.00) 1.00 (0.00, 2.00) 0.00 (−1.00, 0.00)
Worst case 0.00 (0.00, 2.00) 0.00 (−1.00, 1.00) 0.00 (−1.00, 2.00) 1.00 (−1.00, 2.00) 2.00 (−1.00, 2.00) 0.00 (−1.00, 1.00)
Values are shown as median (95% confidence interval)
APAP auto-adjusting continuous positive airway pressure, NOT nocturnal oxygen therapy
Table 7 Carry-over, treatment, and period effects after adjusting for each other
Type Carry-over Treatment Period
Multiple imputation 0.981 (−0.523, 2.48) 0.143 (−0.116, 0.401) − 0.257 (− 0.520, 0.00658)
Best case 0.518 (− 1.78, 2.81) −0.0227 (− 0.609, 0.563) 0.523 (− 0.0635, 1.109)
Worst case −0.400 (−4.49, 3.69) 0.318 (− 0.850, 1.49) −1.32 (−2.49, − 0.150)
Values are shown with confidence intervals
Auto-adjusting continuous positive airway pressure (APAP) was set as the reference treatment
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preferences, specifically for oxygen therapy. Three adults
found the noise disturbing to the point where they had
trouble sleeping, or that it disturbed other family mem-
bers. Overall, in terms of machine mechanics, the big-
gest disadvantage for APAP usage is an uncomfortable
mask, whereas oxygen therapy’s mask/nasal cannula is
unstable and also has low pressures that do not feel as
useful to patients.
Physiologically, patients found both positive and nega-
tive effects. Oxygen therapy caused a dryness/coldness
in the throat, skin, or nose for three adults, which also
reflects an obstacle to adherence in individuals with
chronic obstructive pulmonary disease (COPD) [37]. In
contrast, in one child the oxygen helped clear yellowness
of the eyes. The APAP treatment made patients feel as if
their airways were being cleared, thus making it easier to
breathe. Many participants also discussed a change in
sleep patterns as a result of the treatment: 10 were posi-
tive changes, and 4 were negative changes. Many re-
sponses were given in a general context, instead of being
therapy specific; however, for the specified responses,
three participants found it easier to sleep with the APAP
machine compared with the oxygen supply. However, in
almost every case it took the patients a few days to ad-
just to the new sleeping routines (wearing a mask, sleep-
ing in a certain way, and so on). Randerath et al. [31]
also found that PAP machines improved rapid eye move-
ment (REM) sleep and decreased daytime sleepiness
after 6 weeks of use in OSA patients.
In terms of psychological and social factors, both using
PAP and oxygen therapy, many studies discuss the im-
portance of the patient’s self-efficacy and belief in their
ability to use the treatment on a daily basis and also
their expectations regarding the effects of treatment [32,
33, 37, 40, 41]. For example, when COPD patients felt
that oxygen therapy was improving their day-to-day
lives, they were more likely to adhere to the 15-h oxygen
requirement [42], similar to the children with OSA of-
fered CPAP by Parshad et al. [40]. In the POMS2a trial,
when asked if the patients felt any changes in day-to-day
symptoms, eight claimed to feel no different, with one
participant only feeling better for 1 day after treatment
and then returning to baseline. One participant felt that
using the treatment was detrimental in her day-to-day life,
primarily due to loss of sleep; however, the remaining par-
ticipants claimed an improvement in one aspect or an-
other: five participants felt physical differences (clearing
headaches, improve breathing, and so on), and four partic-
ipants felt improvements in alertness during the day. This
is important to examine further since previous literature
shows that a positive change in day-to-day life increases
compliance with the treatment [37, 40].
The impact that a therapy has on the social interac-
tions of a patient also affects the feasibility of a
treatment. Two adults, who had families, expressed an
inconvenience caused by the machines in the sleeping
patterns of the family. Additionally, one child expressed
that he was concerned he might knock over the APAP
machine and thus cause others in the house to wake up.
Family factors, inconvenience to others, and self-image
with family and friends all play a role in compliance with
oxygen therapy or PAP machines [32, 33, 37].
Fortunately, every participant in the current study
showed no difficulty in learning how to operate either
the APAP machine or oxygen concentrator, which in-
creases the likelihood of compliance with the treatment.
In contrast to the wider literature, none of our patients
or parents expressed any concerns for APAP or NOT.
Commonly, when discussing oxygen therapy, many par-
ticipants express a fear of becoming addicted to oxygen
or of having side-effects from too much oxygen [7, 43].
This concern was largely absent from the current study,
which may also be because most participants did not
have any prior knowledge of the two therapies before
their introduction to this study.
Overnight oximetry at baseline
The majority of patients who enrolled in this study had
mean and nadir oxygen saturations lower than that re-
ported in people without sleep-disordered breathing in
the general population [26–29]. There are few data on
overnight oximetry in asymptomatic adults and the re-
ported data may be for the median overnight oxygen sat-
uration [26, 28, 29], precluding comparison with our
mean overnight oxygen saturation data. Daytime SpO2 is
lower in patients with SCA with lower haemoglobin F
(HbF) [44], and hydroxyurea, which is typically associ-
ated with an increase in HbF, may increase daytime
SpO2 [45]. In two children, hydroxyurea therapy was as-
sociated with improvement in OSA [46] but there are
few data on any effect on overnight mean or nadir oxy-
gen saturation. Our data do not suggest that overnight
oxygen desaturation is cured by hydroxyurea use, but
more data are needed.
Quality of Life
Measurements of quality of life were feasible at baseline
using the PedsQL but there were difficulties in obtaining
repeat measures because of the length of time required
to complete the questionnaires. For the Phase II trial we
will ensure that patients fill in the relatively simple Euro-
Qol quality of life questionnaires [47].
Feasibility of using tablet technology
One of the aims of the trial was to establish the feasibil-
ity of tablet technology to collect daily pain data. Tablet
technology was acceptable to patients with satisfactory
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levels of completion, but a simpler system might reduce
the proportion of missing values.
Safety
Although three patients experienced significant pain dur-
ing overnight respiratory support, there was no evidence
of rebound pain in the washout period after the 7-day ap-
plication of APAP. Analysis of the number of pain days
showed that, although both treatments were associated
with a median reduction in the number of pain days, the
data were not compatible with any clinically meaningful
difference between the effects of APAP and NOT. There
was some evidence for erythroid suppression with both
APAP and NOT, but with no difference between them.
The slight reduction in haemoglobin was not considered
clinically significant and nor were the small changes in
lung function in the adults. APAP is considerably cheaper,
an important health economic consideration. However,
the numbers were very small and safety will be an import-
ant endpoint in the planned Phase II trial.
In conclusion, the POMS2a trial shows results on
feasibility, preference, and acceptance of APAP and oxy-
gen therapy that are in line with previous literature for
the same treatment used in other populations, with a
few exceptions. SCA patients expressed concern over
the mask type, machine noise, and ability to sleep during
both the treatments; however, 10/16 of interviewed par-
ticipants, a point estimate of 62.5%, claimed they would
prefer to use APAP as opposed to NOT for overnight re-
spiratory support. In view of the point estimate of pa-
tient preference for APAP, and no evidence that pain
was worse during APAP or in washout after APAP, with
no evidence of clinically significant bone marrow sup-
pression, and improved ease of collection of adherence
data and lower cost it was decided to proceed with a
Phase II trial of 6 months therapy with APAP versus
standard care to assess its effects on pain, quality of life,
and cognitive function [14].
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